1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors
作者:Christopher Asquith、Paulo Godoi、Rafael Couñago、Tuomo Laitinen、John Scott、Christopher Langendorf、Jonathan Oakhill、David Drewry、William Zuercher、Panayiotis Koutentis、Timothy Willson、Andreas Kalogirou
DOI:10.3390/molecules23051221
日期:——
demonstrate for the first time that 4H-1,2,6-thiadiazin-4-one (TDZ) can function as a chemotype for the design of ATP-competitive kinase inhibitors. Using insights from a co-crystal structure of a 3,5-bis(arylamino)-4H-1,2,6-thiadiazin-4-one bound to calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2), several analogues were identified with micromolar activity through targeted displacement of
我们首次证明了4H-1,2,6-噻二嗪-4-酮(TDZ)可以用作设计ATP竞争性激酶抑制剂的化学型。利用结合到钙/钙调蛋白依赖性蛋白激酶2(CaMKK2)的3,5-双(芳基氨基)-4H-1,2,6-噻二嗪-4-酮的共晶体结构获得的见解,得到了几种类似物通过结合的水分子在活性位点的靶向置换而具有微摩尔活性。由于TDZ类似物与其2,4-二苯并嘧啶对立物相比显示出降低的滥交性,因此它们代表了开发高选择性激酶抑制剂的起点。